

SEP-09-2004 17:05

DEPARTMENT OF HEALTH AND HUMAN SERVICES
HEALTH CARE FINANCING ADMINISTRATION

FORM APPROVED

TRANSMITTAL AND NOTICE OF APPROVAL OF
STATE PLAN MATERIAL

1. TRANSMITTAL NUMBER.

04-09

2. STATE:

Minnesota

FOR: HEALTH CARE FINANCING ADMINISTRATION

3. PROGRAM IDENTIFICATION: TITLE XIX OF THE
SOCIAL SECURITY ACT (MEDICAID)TO: REGIONAL ADMINISTRATOR
HEALTH CARE FINANCING ADMINISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES4. PROPOSED EFFECTIVE DATE
July 1, 2004

5. TYPE OF PLAN MATERIAL (Check One):

☒ NEW STATE PLAN ☒ AMENDMENT TO BE CONSIDERED AS NEW PLAN ☐ AMENDMENT

COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AMENDMENT (Separate Transmittal for each amendment)

6. FEDERAL STATUTE/REGULATION CITATION

42 CFR 440.120(a)

42 CFR 447.201(b) - per state on 6/8/04

7. FEDERAL BUDGET IMPACT:

a. FFY '04 (\$2,750)

b. FFY '05 (\$11,000)

8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT:

Att. 3.1-A, pp. 46-46f

Att. 3.1-B, pp. 45-45f

9. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION
OR ATTACHMENT (If Applicable):

same

10. SUBJECT OF AMENDMENT:

Services: Prescribed Drugs

11. GOVERNOR'S REVIEW (Check One):

☐ GOVERNOR'S OFFICE REPORTED NO COMMENT☒ OTHER, AS SPECIFIED:☒ COMMENTS OF GOVERNOR'S OFFICE ENCLOSED☒ NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL

12. SIGNATURE OF STATE AGENCY OFFICIAL:

16. RETURN TO:

Stephanie Schwartz
Federal Relations Unit
Minnesota Department of Human Services
444 Lafayette Road No.
St. Paul, MN 55155-3852

13. TYPED NAME:

// Mary B. Kennedy - signature //

14. TITLE:

Medicaid Director

15. DATE SUBMITTED:

April 30, 2004

FOR REGIONAL OFFICE USE ONLY

17. DATE RECEIVED: 4/30/04

18. DATE APPROVED: 9/9/04

PLAN APPROVED - ONE COPY ATTACHED

19. EFFECTIVE DATE OF APPROVED MATERIAL:

07/01/04

20. SIGNATURE OF REGIONAL OFFICIAL:

Cheryl A. Harris
Associate Regional Administrator
Division of Medicaid and Children's Health

21. TYPED NAME: Cheryl A. Harris

23. REMARKS:

STATE: MINNESOTA

ATTACHMENT 3 1-A

Effective: July 1, 2004

Page 46

TN: 04-09

Approved: SEP 09 2004

Supersedes: 03-36

12.a. Prescribed drugs.

The following providers are eligible for payment for dispensing prescribed drugs:

- (1) A pharmacy that is licensed by the Minnesota Board of Pharmacy.
- (2) An out of state pharmacy that complies with the licensing and certification requirements of the state in which it is located.
- (3) A physician located in a local trade area where there is no Medicaid enrolled pharmacy. To be eligible for payment, the physician shall personally dispense the prescribed drug according to applicable Minnesota Statutes and shall adhere to the labeling requirements of the Minnesota Board of Pharmacy.
- (4) A physician or nurse practitioner employed by or under contract with a community health board, for the purposes of communicable disease control.

The following limitations apply to pharmacy services:

- (1) With the exception noted below, the prescribed drug must be a drug or compounded prescription that is made by a manufacturer that has a rebate with the Centers for Medicare & Medicaid Services (CMS) and included in the Minnesota Department of Human Services drug formulary. The formulary is established in accordance with §1927(d)(4) of the Social Security Act. See Drug Formulary.
 - A prescribed drug is covered if it has Investigational New Drug (IND) status with an IND number by the United States Food and Drug Administration (FDA), even though the manufacturer does not have a rebate with CMS. When the prescribed drug receives FDA approval, the manufacturer must have a rebate agreement for the drug in order for the drug to be covered.
- (2) A prescribed drug must be dispensed in the quantity specified on the prescription unless the pharmacy is using unit dose dispensing, the specified quantity is not available in the pharmacy when the prescription is dispensed, or the specified quantity exceeds a 34-day supply.

MINNESOTA

Effective: July 1, 2004

TN: 04-09

Approved: SEP 09 2004

Supersedes: 03-36

Page 46a

12.a. Prescribed drugs. (continued)

- (3) Effective October 1, 2003, the dispensed quantity of a prescribed drug must not exceed a 34-day supply, unless authorized by the Department. The following do not require prior authorization:
 - (a) over-the-counter medications must be dispensed in the manufacturer's unopened package, and Sorbitol may be repackaged.
 - (b) contraceptive drugs may be dispensed in quantities not exceeding a 90-day supply.
- (4) An initial or refill prescription for a maintenance drug shall be dispensed in not less than a 30-day supply unless the pharmacy is using unit dose dispensing. No additional dispensing fee shall be paid until that quantity is used by the recipient.
- (5) Except as provided in item (6), coverage of the dispensing fee for a particular pharmacy or dispensing physician for a maintenance drug for a recipient is limited to one fee per 30-day supply.
- (6) More than one dispensing fee per calendar month for a maintenance drug for a recipient is allowed if:
 - (a) the record kept by the pharmacist or dispensing physician documents that there is a significant chance of overdose by the recipient if a larger quantity of drug is dispensed, and if the pharmacist or dispensing physician writes a statement of this reason on the prescription; or
 - (b) the drug is clozapine.
- (7) A refill of a prescription must be authorized by the practitioner. Refilled prescriptions must be documented in the prescription file, initialed by the pharmacist who refills the prescription, and approved by the practitioner as consistent with accepted pharmacy practice under Minnesota Statutes.

~~SECRET~~ ~~CONFIDENTIAL~~
Effective: July 1, 2004
TN: 04-09
Approved: SEP 09 2004
Supersedes: 03-36

ATTACHMENT 1 A

Page 46b

12.a. Prescribed drugs. (continued)

- (8) Generic drugs must be dispensed to recipients if:
- (a) the generically equivalent drug is approved and is determined as therapeutically equivalent by the FDA;
 - (b) in the pharmacist's or dispensing physician's professional judgment, the generically equivalent drug is safely interchangeable with the prescribed drug;
 - (c) the charge for the substituted generically equivalent drug does not exceed the charge for the drug originally prescribed; and
 - (d) the practitioner has not written in his or her own handwriting "Dispense as Written-Brand Necessary" or "DAW-Brand Necessary" on the prescription. Effective January 2, 2004, even if the practitioner has written "Dispense as Written-Brand Necessary" or "DAW-Brand Necessary" on the prescription, authorization is required to dispense brand name drugs.
- (9) The following limits apply to drugs dispensed under unit dose packaging:
- (a) Dispensing fees for drugs dispensed in unit dose packaging shall not be paid more often than once per calendar month or when a minimum of 30 dosage units have been dispensed, whichever results in the lesser number of dispensing fees.
 - (b) Only one dispensing fee per calendar month will be paid for each maintenance drug, regardless of the type of unit dose system used or the number of times during the month the pharmacist dispenses the drug.
 - (c) An additional dispensing fee per prescription shall be paid to pharmacists using an in-pharmacy packaged unit dose system (except for over-the-counter medications) approved by the Board of Pharmacy for the return of drugs when dispensing to recipients in a long-term care facility if:

MINNESOTA

ATTACHMENT 3 1-2

Effective: July 1, 2004

Page 46c

TN: 04-09

Approved: SEP 09 2004

Supersedes: 03-36

12.a. Prescribed drugs. (continued)

- (i) the pharmacy is registered with the Department by filing an addendum to the provider agreement;
- (ii) a minimum 30-day supply of the drug is dispensed, although a lesser quantity may be dispensed for an acute course of medication therapy for a specified time period;
- (iii) the national drug code from the drug stock container used to fill the unit dose package is identified to the Department;
- (iv) the unit dose package containing the drug meets the packaging standards set forth in Minnesota Statutes that govern the return of unused drugs to the pharmacy for reuse and documentation that unit dose packaging meets permeability standards of the Board of Pharmacy; and
- (v) the pharmacy provider credits the Department for the actual acquisition cost of all unused drugs that are eligible for return and reuse.

(10) Delivery charges for a drug are not covered.

Drug Formulary:

All drugs and compounded prescriptions made by a manufacturer that are covered under a signed rebate agreement with CMS are included in the drug formulary, with the following limitations on coverage:

- (1) Over-the-counter drugs must be listed in the Department's "Health Care Programs Provider Manual," on a remittance advice message, or in a Department-issued provider update. The following over-the-counter drugs are covered only when prescribed by a licensed practitioner or a licensed pharmacist who meets standards established by the Department, in consultation with the Board of Pharmacy:

STATE: MINNESOTA

ATTACHMENT 3.1-A

Effective: July 1, 2004

Page 46d

TN: 04-09

Approved: SEP 09 2004

Supersedes: 03-36

12.a. Prescribed drugs. (continued)

- (a) antacids;
- (b) acetaminophen;
- (c) aspirin;
- (d) family planning products;
- (e) insulin;
- (f) products for the treatment of lice;
- (g) vitamins for adults with documented vitamin deficiencies;
- (h) vitamins for children under the age of seven and pregnant or nursing women; and
- (i) any other drug identified by the Department, in consultation with the Drug Formulary Committee.

(2) The following categories of drugs are not covered pursuant to §1927(d) (2):

- (a) Effective August 1, 2003, drugs used for weight loss, except that medically necessary lipase inhibitors may be covered for recipients with type 2 diabetes.
- (b) Agents when used to promote fertility.
- (c) Agents when used for cosmetic purposes or hair growth.
- (d) Covered outpatient drugs that the manufacturer seeks to require as a condition of sale that associated tests or monitoring services be purchased exclusively from the manufacturer or its designee.
- (e) Drugs described in §107(c) (3) of the Drug Amendments of 1962 and identical, similar, or related drugs (within the meaning of 21 CFR §310.6(b) (1) (DESI drugs)).

(3) The following categories of drugs are covered with limitations pursuant to §1927(d) (2):

- (a) Agents when used for the symptomatic relief of cough and colds must be listed in the Department's "Minnesota Health Care Programs Provider Manual," on a remittance advice message, or in a Department-issued provider update.

STATE: MINNESOTA
Effective: July 1, 2004
TN: 04-09
Approved:
Supersedes: ~~SEP 03 2004~~ 03-36 2004

ATTACHMENT 3.1-A
Page 46e

12.a. Prescribed drugs. (continued)

- (b) Prescription vitamins and mineral products for children, pregnant and nursing women, and recipients with documented vitamin deficiencies. The limitations do not apply to fluoride treatments. Prenatal vitamins are restricted to pregnant and nursing women.

Notwithstanding the above paragraph, some vitamins and mineral products are available for the treatment or prevention of certain diseases:

- (1) niacin;
- (2) calcium and calcium/vitamin D; and
- (3) generic preparations equivalent to Ocuville.

Prior Authorization:

A. The following requirements, found in §1927(d)(5) of the Act, are met:

- The prior authorization program provides a response by telephone or other telecommunication device within 24 hours of a request
- The prior authorization program provides for the dispensing of at least a 72-hour supply of a covered drug in an emergency situation (except for those drugs that are excluded or restricted from coverage, as noted above)

B. Based on the requirements in §1927, the State has the following policies for the supplemental drug rebate program for Medicaid recipients:

- 1) The single-state model rebate agreement between the State and drug manufacturers for drugs provided to Medicaid recipients, submitted to CMS on February 17, 2004 and entitled "State of Minnesota Supplemental Rebate Agreement," has been approved authorized by CMS.

The single-state rebate agreements developed upon this model agreement will be terminated according to the provisions in those agreements and will precede participating in, and collecting supplemental rebates from, the Michigan Multi-State Pooling Agreement.

STATE: MINNESOTA
Effective: July 1, 2004
TN: 04-09
Approved: SEP 09 2004
Supersedes: 03-36

ATTACHMENT 3.1-A
Page 46f

12.a. Prescribed drugs. (continued)

- 2) CMS has authorized the State of Minnesota to enter into the Michigan Multi-State Pooling Agreement (MMSPA). The amendment to the Supplemental Drug Rebate Agreement was submitted to CMS on April 30, 2004 and has been authorized by CMS.
- 3) Supplemental drug rebates received by the State in excess of those required under the national drug rebate agreement will be shared with the Federal government on the same percentage basis as applied under the national drug rebate agreement.
- 4) Manufacturers with supplemental rebate agreements are allowed to audit utilization data.
- 5) The unit rebate amount is confidential and will not be disclosed except in accordance with §1927(b)(3)(D) of the Act.
- 6) A drug that the Department determines comes within its single-state or multi-state supplemental drug rebate program for Medicaid recipients as allowed by §1927, but for which a manufacturer has not signed a supplemental drug rebate agreement approved authorized by CMS, will be prior authorized.

Even if a manufacturer has not signed a supplemental drug rebate agreement, there is never prior authorization for any atypical antipsychotic drug prescribed for the treatment of mental illness if:

- there is no generically equivalent drug available; and
- the drug was initially prescribed for the recipient before July 1, 2003; or
- the drug is part of the recipient's current course of treatment.

STATE: MINNESOTA

ATTACHMENT 3.1-B

Effective: July 1, 2004

Page 45

TN: 04-09

Approved:

Supersedes: ^{SEP 09 2004} 03-36

12.a. Prescribed drugs.

The following providers are eligible for payment for dispensing prescribed drugs:

- (1) A pharmacy that is licensed by the Minnesota Board of Pharmacy.
- (2) An out of state pharmacy that complies with the licensing and certification requirements of the state in which it is located.
- (3) A physician located in a local trade area where there is no Medicaid enrolled pharmacy. To be eligible for payment, the physician shall personally dispense the prescribed drug according to applicable Minnesota Statutes and shall adhere to the labeling requirements of the Minnesota Board of Pharmacy.
- (4) A physician or nurse practitioner employed by or under contract with a community health board, for the purposes of communicable disease control.

The following limitations apply to pharmacy services:

- (1) With the exception noted below, the prescribed drug must be a drug or compounded prescription that is made by a manufacturer that has a rebate with the Centers for Medicare & Medicaid Services (CMS) and included in the Minnesota Department of Human Services drug formulary. The formulary is established in accordance with §1927(d)(4) of the Social Security Act. See Drug Formulary.
 - A prescribed drug is covered if it has Investigational New Drug (IND) status with an IND number by the United States Food and Drug Administration (FDA), even though the manufacturer does not have a rebate with CMS. When the prescribed drug receives FDA approval, the manufacturer must have a rebate agreement for the drug in order for the drug to be covered.
- (2) A prescribed drug must be dispensed in the quantity specified on the prescription unless the pharmacy is using unit dose dispensing, the specified quantity is not available in the pharmacy when the prescription is dispensed, or the specified quantity exceeds a 34-day supply.

STATE: MINNESOTA

ATTACHMENT 3.1-B

Effective: July 1, 2004

Page 45a

TN: 04-09

SEP 09 2004

Approved:

Supersedes: 03-36

12.a. Prescribed drugs. (continued)

- (3) Effective October 1, 2003, the dispensed quantity of a prescribed drug must not exceed a 34-day supply, unless authorized by the Department. The following do not require prior authorization:
 - (a) over-the-counter medications must be dispensed in the manufacturer's unopened package, and Sorbitol may be repackaged.
 - (b) contraceptive drugs may be dispensed in quantities not exceeding a 90-day supply.
- (4) An initial or refill prescription for a maintenance drug shall be dispensed in not less than a 30-day supply unless the pharmacy is using unit dose dispensing. No additional dispensing fee shall be paid until that quantity is used by the recipient.
- (5) Except as provided in item (6), coverage of the dispensing fee for a particular pharmacy or dispensing physician for a maintenance drug for a recipient is limited to one fee per 30-day supply.
- (6) More than one dispensing fee per calendar month for a maintenance drug for a recipient is allowed if:
 - (a) the record kept by the pharmacist or dispensing physician documents that there is a significant chance of overdose by the recipient if a larger quantity of drug is dispensed, and if the pharmacist or dispensing physician writes a statement of this reason on the prescription;
or
 - (b) the drug is clozapine.
- (7) A refill of a prescription must be authorized by the practitioner. Refilled prescriptions must be documented in the prescription file, initialed by the pharmacist who refills the prescription, and approved by the practitioner as consistent with accepted pharmacy practice under Minnesota Statutes.

Original: MINNESOTA

ALLEGHENY STATE

Effective: July 1, 2004

Page 45b

TN: 04-09

Approved: SEP 09 2004

Supersedes: 03-36

12.a. Prescribed drugs. (continued)

- (8) Generic drugs must be dispensed to recipients if:
- (a) the generically equivalent drug is approved and is determined as therapeutically equivalent by the FDA;
 - (b) in the pharmacist's or dispensing physician's professional judgment, the generically equivalent drug is safely interchangeable with the prescribed drug;
 - (c) the charge for the substituted generically equivalent drug does not exceed the charge for the drug originally prescribed; and
 - (d) the practitioner has not written in his or her own handwriting "Dispense as Written-Brand Necessary" or "DAW-Brand Necessary" on the prescription. Effective January 2, 2004, even if the practitioner has written "Dispense as Written-Brand Necessary" or "DAW-Brand Necessary" on the prescription, authorization is required to dispense brand name drugs.
- (9) The following limits apply to drugs dispensed under unit dose packaging:
- (a) Dispensing fees for drugs dispensed in unit dose packaging shall not be paid more often than once per calendar month or when a minimum of 30 dosage units have been dispensed, whichever results in the lesser number of dispensing fees.
 - (b) Only one dispensing fee per calendar month will be paid for each maintenance drug, regardless of the type of unit dose system used or the number of times during the month the pharmacist dispenses the drug.
 - (c) An additional dispensing fee per prescription shall be paid to pharmacists using an in-pharmacy packaged unit dose system (except for over-the-counter medications) approved by the Board of Pharmacy for the return of drugs when dispensing to recipients in a long-term care facility if: